PMID- 12788333
OWN - NLM
STAT- MEDLINE
DCOM- 20030820
LR  - 20191210
IS  - 0149-7634 (Print)
IS  - 0149-7634 (Linking)
VI  - 27
IP  - 3
DP  - 2003 May
TI  - The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine 
      (MDMA).
PG  - 199-217
AB  - 3,4-Methylenedioxymethamphetamine (MDMA) is a relatively novel drug of abuse and 
      as such little is currently known of its behavioural pharmacology. This review 
      aims to examine whether MDMA represents a novel class of abused drug. MDMA is 
      known as a selective serotonergic neurotoxin in a variety of animal species but 
      acutely it is a potent releaser and/or reuptake inhibitor of presynaptic 
      serotonin, dopamine, noradrenaline, and acetylcholine. Interaction of these 
      effects contributes to its behavioural pharmacology, in particular its effects on 
      body temperature. Drug discrimination studies indicate that MDMA and related 
      drugs produce unique interoceptive effects which have led to their classification 
      as entactogens. This is supported by results from other behavioural paradigms 
      although there is evidence for dose dependency of MDMA-specific effects. MDMA 
      also produces conditioned place preference but is not a potent reinforcer in 
      self-administration studies. These unique behavioural effects probably underlie 
      its current popularity. MDMA is found in the street drug ecstasy but it may not 
      be appropriate to equate the two as other drugs are routinely found in ecstasy 
      tablets
FAU - Cole, Jon C
AU  - Cole JC
AD  - Department of Psychology, University of Liverpool, L69 7ZA, Liverpool, UK. 
      j.c.cole@liv.ac.uk
FAU - Sumnall, Harry R
AU  - Sumnall HR
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Carrier Proteins)
RN  - 0 (Hallucinogens)
RN  - 0 (Illicit Drugs)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Membrane Transport Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 0 (Slc6a4 protein, mouse)
RN  - 0 (Slc6a4 protein, rat)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Animals
MH  - Behavior, Animal/*drug effects
MH  - Brain/drug effects
MH  - Carrier Proteins/drug effects
MH  - Conditioning, Psychological/drug effects
MH  - Discrimination Learning/drug effects
MH  - Disease Models, Animal
MH  - Dose-Response Relationship, Drug
MH  - Drug Evaluation, Preclinical/psychology
MH  - Hallucinogens/metabolism/*pharmacology
MH  - Illicit Drugs/metabolism/pharmacology
MH  - Membrane Glycoproteins/drug effects
MH  - *Membrane Transport Proteins
MH  - Mice
MH  - N-Methyl-3,4-methylenedioxyamphetamine/metabolism/*pharmacology
MH  - *Nerve Tissue Proteins
MH  - Rats
MH  - Reward
MH  - Serotonin Plasma Membrane Transport Proteins
RF  - 313
EDAT- 2003/06/06 05:00
MHDA- 2003/08/21 05:00
CRDT- 2003/06/06 05:00
PHST- 2003/06/06 05:00 [pubmed]
PHST- 2003/08/21 05:00 [medline]
PHST- 2003/06/06 05:00 [entrez]
AID - S0149763403000319 [pii]
AID - 10.1016/s0149-7634(03)00031-9 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2003 May;27(3):199-217. doi: 
      10.1016/s0149-7634(03)00031-9.